Skip to main content
SpringerLink
Log in

Is it time to change our vision of tumor metabolism prior to immunotherapy?

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Takada K, Toyokawa G, Okamoto T, et al. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on 18 F-fluorodeoxyglucose positron emission tomography/computed tomography. Cancer Med. 2017;6(11):2552–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Liu J, Dong M, Sun X, et al. Prognostic value of 18F-FDG PET7CT in surgical non-small cell lung cancer: a meta-analysis. PLoS One. 11(1):e0146195.

  3. Toyokawa G, Takada K, Okamoto T, et al. Elevated metabolic activity on 18F-FDG PET/CT is associated with the expression of EZH2 in non-small cell lung cancer. Anticancer Res. 2017;37:1393–402.

    Article  PubMed  Google Scholar 

  4. Lopci E, Rossi S. Tumor metabolism and prognostic role of EZH2 in non-small cell lung cancer. Transl Cancer Res. 2017;6:S982–8.

    Article  Google Scholar 

  5. Palsson-McDermott EM, O’Neill LAJ. The Warburg effect then and now: from cancer to inflammatory diseases. BioEssays. 2013;35:965–73.

    Article  CAS  PubMed  Google Scholar 

  6. Lopci E, Toschi L, Grizzi F, et al. Correlation of metabolic information on FD-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging. 2016;43:1954–61.

    Article  CAS  PubMed  Google Scholar 

  7. Horne ZD, Jack R, Gray ZT, et al. Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. J Surg Res. 2011;171:1–5.

    Article  CAS  PubMed  Google Scholar 

  8. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses to inhibiting adaptive immune resistence. Nature. 2014;515:568–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Lopci E, Grizzi F, Russo C, et al. Early and delayed evaluation of solid tumours with 64Cu-ATSM PET/CT: a pilot study on semiquantitative and computer-aided fractal geometry analysis. Nucl Med Commun. 2017;38:340–6.

    Article  PubMed  Google Scholar 

  10. Rashidian M, Ingram JR, Dougan M, et al. Predicting the response to CTLA-4 blocjage by longitudinal noninvasive monitoring of CD8 T cells. J Exp Med. 2017;214:2243.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

The Italian Association for Research on Cancer (AIRC – Associazione Italiana per la Ricerca sul Cancro) is acknowledged for their support of this research.

Author information

Authors and Affiliations

  1. Department of Immunology and Inflammation, Humanitas Clinical and Research Hospital, Rozzano, Milan, Italy

    Fabio Grizzi

  2. Nuclear Medicine, Humanitas Clinical and Research Hospital, Via Manzoni 56, 20089, Rozzano, MI, Italy

    Angelo Castello & Egesta Lopci

Authors
  1. Fabio Grizzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Angelo Castello
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Egesta Lopci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Egesta Lopci.

Ethics declarations

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Potential conflicts of interest

A.C. is supported by a fellowship related to the grant Nr. 18,923 provided by AIRC to E.L.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grizzi, F., Castello, A. & Lopci, E. Is it time to change our vision of tumor metabolism prior to immunotherapy?. Eur J Nucl Med Mol Imaging 45, 1072–1075 (2018). https://doi.org/10.1007/s00259-018-3988-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-018-3988-1

Search

Navigation